keyword
MENU ▼
Read by QxMD icon Read
search

renal carcinoma

keyword
https://www.readbyqxmd.com/read/28239880/long-term-use-of-oral-nucleos-t-ide-analogues-for-chronic-hepatitis-b-does-not-increase-cancer-risk-a-cohort-study-of-44-494-subjects
#1
G L-H Wong, Y-K Tse, T C-F Yip, H L-Y Chan, K K-F Tsoi, V W-S Wong
BACKGROUND: Patients with chronic hepatitis B (CHB) need long-term antiviral treatment with nucleos(t)ide analogues (NA). Animal studies suggest that some NA may increase cancer risk, but human data are lacking. AIM: To investigate cancer risks in patients with or without NA treatment. METHODS: We conducted a territory-wide cohort study using the database from Hospital Authority in Hong Kong. The diagnosis of CHB and various malignancies was based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes between 2000 and 2012...
February 27, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28239466/nivolumab-induced-myxedema-crisis
#2
Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu, Tarik Hadid
BACKGROUND: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxedema crisis induced by nivolumab in a patient with metastatic squamous cell carcinoma of lung. CASE PRESENTATION: Fifty three-year old woman with metastatic squamous cell carcinoma currently on treatment with nivolumab presented with diffuse facial and tongue swelling, slurred speech, depressed mentation, fatigue and weakness...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28237787/re-targeting-renal-cell-carcinoma-with-a-hif-2-antagonist
#3
James E Ferguson, Surena F Matin
No abstract text is available yet for this article.
February 23, 2017: European Urology
https://www.readbyqxmd.com/read/28237282/the-current-role-of-biopsy-in-the-diagnosis-of-renal-tumors
#4
Nicole Curci, Elaine M Caoili
The role of percutaneous renal mass biopsy has continued to grow in the last decade. The incidence of small (≤4cm) renal masses has increased dramatically over the past 15 years, attributed to increased use of cross-sectional imaging and subsequent discovery of small renal masses that would otherwise go undetected. Despite increased early detection, there has been no change in the mortality rate from renal cell carcinoma over the past 15 years. Many small renal masses are not life-limiting, and imaging lacks specificity in distinguishing malignant from nonmalignant small renal masses...
February 2017: Seminars in Ultrasound, CT, and MR
https://www.readbyqxmd.com/read/28237279/diagnosis-of-renal-angiomyolipomas-classic-fat-poor-and-epithelioid-types
#5
Masahiro Jinzaki, Stuart G Silverman, Hirotaka Akita, Shuji Mikami, Mototsugu Oya
With the increasing discovery of small renal masses with cross-sectional imaging, there has been the concomitant rise in their treatment. With the intent of early curative surgery for a presumed renal cell carcinoma, many renal masses are being resected at surgery without a confirmed diagnosis. Many of them are benign, and some are angiomyolipomas. The diagnosis of renal angiomyolipoma using imaging is, therefore, is as important as ever. Although most, if not all angiomyolipomas with abundant fat are diagnosed readily, some have too little fat to be detected with imaging...
February 2017: Seminars in Ultrasound, CT, and MR
https://www.readbyqxmd.com/read/28237278/differentiation-of-small-solid-renal-masses-a-pattern-recognition-approach
#6
Sungmin Woo, Seung Hyup Kim
The incidence of small renal masses (SRMs) has shown significant increase owing to more widespread use of cross-sectional imaging. These SRMs include various subtypes of renal cell carcinomas (RCCs) and several types of benign tumors including angiomyolipomas. Differentiation between RCC and benign SRMs is crucial for a patient to receive optimal management. Therefore, it is important for the radiologist to recognize imaging patterns that are characteristic of or diffferentiate between RCCs and benign SRMs, when confronting a SRM...
February 2017: Seminars in Ultrasound, CT, and MR
https://www.readbyqxmd.com/read/28237182/correlation-of-c-met-expression-and-outcome-in-patients-with-renal-cell-carcinoma-treated-with-sunitinib
#7
Katriina Johanna Peltola, Patrick Penttilä, Juhana Rautiola, Heikki Joensuu, Erkki Hänninen, Ari Ristimäki, Petri Bono
BACKGROUND: Treatment of patients with metastatic renal cell carcinoma (mRCC) has improved substantially since the introduction of targeted therapies, but no predictive biomarkers are available. The proto-oncogene c-Met is involved in tumor angiogenesis, development, and metastasis. The main objective was to evaluate c-Met expression in sunitinib-treated patients with mRCC, including patients with bone metastases. METHODS: c-Met expression was analyzed from 137 formalin-fixed paraffin-embedded tumor samples using a validated immunostaining protocol...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28236579/does-ureteral-catheter-insertion-decrease-the-risk-of-urinary-leakage-after-partial-nephrectomy-in-patients-with-renal-cell-carcinoma
#8
Sangjun Yoo, Dalsan You, In Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
INTRODUCTION: We aimed to evaluate the impact of preoperative ureteral catheter insertion on urinary leakage after partial nephrectomy (PN) in patients with renal cell carcinoma. METHODS: We reviewed the data of 893 patients with renal cell carcinoma who underwent PN and divided them according to ureteral catheter placement. The impact of ureteral catheter placement on postoperative urinary leakage was evaluated by using multivariate analysis. RESULTS: Ureteral catheters were inserted in 397 (44...
February 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28236116/clinical-pharmacokinetic-and-pharmacodynamic-profile-of-lenvatinib-an-orally-active-small-molecule-multitargeted-tyrosine-kinase-inhibitor
#9
Ziad Hussein, Hitoshi Mizuo, Seiichi Hayato, Masayuki Namiki, Robert Shumaker
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor-alpha, and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer in the United States (US), European Union (EU), Canada, Japan, and Switzerland. It is also approved in combination with everolimus for the treatment of advanced renal cell carcinoma following ≥1 VEGF-targeted treatment in the US and EU...
February 24, 2017: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/28235946/vhl-promotes-immune-response-against-renal-cell-carcinoma-via-nf-%C3%AE%C2%BAb-dependent-regulation-of-vcam-1
#10
David Labrousse-Arias, Emma Martínez-Alonso, María Corral-Escariz, Raquel Bienes-Martínez, Jaime Berridy, Leticia Serrano-Oviedo, Elisa Conde, María-Laura García-Bermejo, José M Giménez-Bachs, Antonio S Salinas-Sánchez, Ricardo Sánchez-Prieto, Masahiro Yao, Marina Lasa, María J Calzada
Vascular cell adhesion molecule 1 (VCAM-1) is an adhesion molecule assigned to the activated endothelium mediating immune cells adhesion and extravasation. However, its expression in renal carcinomas inversely correlates with tumor malignancy. Our experiments in clear cell renal cell carcinoma (ccRCC) cell lines demonstrated that von Hippel Lindau (VHL) loss, hypoxia, or PHD (for prolyl hydroxylase domain-containing proteins) inactivation decreased VCAM-1 levels through a transcriptional mechanism that was independent of the hypoxia-inducible factor and dependent on the nuclear factor κB signaling pathway...
February 24, 2017: Journal of Cell Biology
https://www.readbyqxmd.com/read/28235487/cnpy2-promoted-the-proliferation-of-renal-cell-carcinoma-cells-and-increased-the-expression-of-tp53
#11
Hidefumi Taniguchi, Saya Ito, Takashi Ueda, Yukako Morioka, Naruhiro Kayukawa, Akihisa Ueno, Hideo Nakagawa, Atsuko Fujihara, So Ushijima, Motohiro Kanazawa, Fumiya Hongo, Osamu Ukimura
Renal cell carcinoma (RCC) is the most common type of kidney cancer. However, the mechanisms underlying the progression of the disease are not well understood. The data in this report suggest that canopy FGF signaling regulator 2 (CNPY2) is a promoter of RCC progression. We found that CNPY2 significantly promoted growth of RCC cells and upregulated TP53 gene expression. Although TP53 is widely known as a tumor suppressor, in RCC TP53 promoted tumor cell growth. A typical p53 target gene, CDKN1A, was upregulated by both p53 and CNPY2 in RCC cells, suggesting that CNPY2 increased the expression level of TP53...
February 21, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28230776/effects-and-side-effects-of-using-sorafenib-and-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#12
REVIEW
Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28230236/a-proposal-of-post-operative-nomogram-for-overall-survival-in-patients-with-renal-cell-carcinoma-and-venous-tumor-thrombus
#13
Liangyou Gu, Zihuan Wang, Luyao Chen, Xin Ma, Hongzhao Li, Wenyuan Nie, Cheng Peng, Xintao Li, Yu Gao, Xu Zhang
OBJECTIVE: To identify the predictors of overall survival (OS) and create a post-operative prognostic model for patients with renal cell carcinoma (RCC) and venous tumor thrombus (VTT). PATIENTS AND METHODS: The study cohort included patients with RCC and VTT that underwent full surgical resection between 2006 and 2016. Univariate and multivariate analyses were used to determine the prognostic factors of OS. A nomogram was developed and internally calibrated by bootstrap resampling method...
February 23, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28229842/-thyroid-metastasis-as-the-initial-presentation-of-an-asymptomatic-clear-cell-renal-carcinoma
#14
Janine Carmelino, Ana Paula Tavares, Ana Crespo, José Mário Coutinho, António Lázaro, Vasco Ribeiro, Eduardo Barroso
INTRODUCTION: Clear cell renal carcinoma metastases to the thyroid gland are rare and only diagnosable after an immunohistochemistry analysis of the histological sample. The purpose of this article is to report a case of thyroid metastasis as the initial presentation of a clear cell renal carcinoma. CASE REPORT: Male patient with a solid nodule in the left lobe of the thyroid, 5.3 cm in diameter, suspicious of malignancy, for which a total thyroidectomy with central compartment lymphadenectomy was performed...
November 2016: Acta Médica Portuguesa
https://www.readbyqxmd.com/read/28224821/lenvatinib-for-use-in-combination-with-everolimus-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-following-one-prior-anti-angiogenic-therapy
#15
Aine O'Reilly, James Larkin
In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents have demonstrated efficacy in this setting. Here in we profile one such therapy, the combination of lenvatinib and everolimus, and discuss the expanded options for therapy available in this setting. Areas covered: In this review, we discuss current algorithms for treatment of mRCC in both the first-line and second-line setting...
March 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28224412/antihypertensive-medication-use-and-risk-of-renal-cell-carcinoma
#16
Joanne S Colt, Jonathan N Hofmann, Kendra Schwartz, Wong-Ho Chow, Barry I Graubard, Faith Davis, Julie Ruterbusch, Sonja Berndt, Mark P Purdue
PURPOSE: Use of antihypertensive medications has been associated with renal cell carcinoma (RCC), but it is unclear whether specific types of medications increase RCC risk independent of the effect of hypertension, or whether the association varies by histologic subtype. To address this question, we analyzed data from a U.S. population-based case-control study of RCC. METHODS: We collected information on participants' use of drugs to treat hypertension, heart problems, weight control, and swelling...
February 21, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28223547/cabozantinib-targets-bone-microenvironment-modulating-human-osteoclast-and-osteoblast-functions
#17
Marco Fioramonti, Daniele Santini, Michele Iuliani, Giulia Ribelli, Paolo Manca, Nicola Papapietro, Filippo Spiezia, Bruno Vincenzi, Vincenzo Denaro, Antonio Russo, Giuseppe Tonini, Francesco Pantano
Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effect of cabozantinib on bone microenvironment using a total human model of primary osteoclasts and osteoblasts.Osteoclasts were differentiated from monocytes isolated from healthy donors; osteoblasts were derived from human mesenchymal stem cells obtained from bone fragments of orthopedic surgery patients...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28223537/reduced-e-cadherin-facilitates-renal-cell-carcinoma-progression-by-wnt-%C3%AE-catenin-signaling-activation
#18
Xinqi Zhang, Mingxi Yang, Hua Shi, Jianxin Hu, Yuanlin Wang, Zhaolin Sun, Shuxiong Xu
Reduced expression of E-cadherin was observed in renal cell carcinoma (RCC). However, its potential clinical value and correlation with WNT/β-catenin signaling in RCC progression was still unclear. Immunohistochemical staining was performed in RCC tissue microarray to examine the expression status and prognosis value of E-cadherin and β-catenin. The potential role of E-cadherin in β-catenin translocation was analyzed with immunobloting assays. A significant negative correlation was observed between E-cadherin and β-catenin expression in RCC tissues...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28223273/pd-l1-studies-across-tumor-types-its-differential-expression-and-predictive-value-in-patients-treated-with-immune-checkpoint-inhibitors
#19
Harriet M Kluger, Christopher R Zito, Gabriela Turcu, Marina Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L Rimm, Yuval Kluger, Lieping Chen, Justine V Cohen, Lucia B Jilaveanu
PURPOSE: With recent approval of inhibitors of PD-1 in melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), extensive efforts are underway to develop biomarkers predictive of response. PD-L1 expression has been most widely studied, and is more predictive in NSCLC than RCC or melanoma. We therefore studied differences in expression patterns across tumor types. EXPERIMENTAL DESIGN: We employed tissue microarrays with tumors from NSCLC, RCC or melanoma and a panel of cell lines to study differences between tumor types...
February 21, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28223235/interleukin-32-inflammation-and-cancer
#20
REVIEW
Jin Tae Hong, Dong Ju Son, Chong Kil Lee, Do-Young Yoon, Dong Hun Lee, Mi Hee Park
Interleukin-32 (IL-32) is a novel cytokine involved in inflammation and cancer development. IL-32 gene consists of eight small exons, and IL-32 mRNA has nine alternative spliced isoforms, and was thought to be secreted because it contains an internal signal sequence and lacks a transmembrane region. IL-32 is initially expressed selectively in activated T cells by mitogen and activated NK cells and their expression is strongly augmented by microbes, mitogens, and other cytokines. The IL-32 is induced mainly by pathogens and pro-inflammatory cytokines, but IL-32 is more prominent in immune cells than in non-immune tissues...
February 14, 2017: Pharmacology & Therapeutics
keyword
keyword
21147
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"